Thioridazine

Sold as Mellaril-S. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Thioridazine (sold as Mellaril-S), first approved Oct 18, 1978, with 0 new uses approved and 0 published complete response letters.

First approved: Oct 18, 1978
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $1.4M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Thioridazine HCl	Part D	$1.4M	-9%	2,910

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

THIORIDAZINE 10 MG TABLET: $0.406 per unitGeneric · -5% in a year
THIORIDAZINE 100 MG TABLET: $0.848 per unitGeneric · +2% in a year
THIORIDAZINE 25 MG TABLET: $0.568 per unitGeneric · 0% in a year
THIORIDAZINE 50 MG TABLET: $0.697 per unitGeneric · -4% in a year

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Oct 18, 1978	Mellaril-SNDA 17923 · New dosage form	Novartis	45	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA